PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, includin… Read more
PDS Biotechnology Corp (PDSB) - Net Assets
Latest net assets as of September 2025: $9.45 Million USD
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has net assets worth $9.45 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.71 Million) and total liabilities ($25.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.45 Million |
| % of Total Assets | 27.24% |
| Annual Growth Rate | N/A |
| 5-Year Change | -29.95% |
| 10-Year Change | -84.48% |
| Growth Volatility | 71.85 |
PDS Biotechnology Corp - Net Assets Trend (2012–2024)
This chart illustrates how PDS Biotechnology Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PDS Biotechnology Corp (2012–2024)
The table below shows the annual net assets of PDS Biotechnology Corp from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $19.00 Million | -27.27% |
| 2023-12-31 | $26.13 Million | -40.61% |
| 2022-12-31 | $44.00 Million | -30.39% |
| 2021-12-31 | $63.21 Million | +132.99% |
| 2020-12-31 | $27.13 Million | +131.92% |
| 2019-12-31 | $11.70 Million | -60.80% |
| 2018-12-31 | $29.84 Million | -52.16% |
| 2017-12-31 | $62.37 Million | -30.14% |
| 2016-12-31 | $89.28 Million | -27.11% |
| 2015-12-31 | $122.48 Million | +540.03% |
| 2014-12-31 | $-27.83 Million | -81.33% |
| 2013-12-31 | $-15.35 Million | -353.56% |
| 2012-12-31 | $-3.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PDS Biotechnology Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17403350400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.54K | 0.07% |
| Other Components | $201.10 Million | 1058.17% |
| Total Equity | $19.00 Million | 100.00% |
PDS Biotechnology Corp Competitors by Market Cap
The table below lists competitors of PDS Biotechnology Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Femasys Inc
NASDAQ:FEMY
|
$30.21 Million |
|
Uangel
KO:072130
|
$30.21 Million |
|
Mitrajaya Holdings Bhd
KLSE:9571
|
$30.22 Million |
|
A1 Yenilenebilir Enerji Üretim A.S.
IS:A1YEN
|
$30.22 Million |
|
Integra Indocabinet Tbk PT
JK:WOOD
|
$30.18 Million |
|
Cambuci S.A
SA:CAMB3
|
$30.17 Million |
|
S.Kijchai Enterprise Public Company Limited
BK:SKN
|
$30.16 Million |
|
Optipharm.CO.LTD
KQ:153710
|
$30.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PDS Biotechnology Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,130,947 to 19,004,848, a change of -7,126,099 (-27.3%).
- Net loss of 37,610,384 reduced equity.
- New share issuances of 22,595,001 increased equity.
- Other factors increased equity by 7,889,284.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-37.61 Million | -197.9% |
| Share Issuances | $22.60 Million | +118.89% |
| Other Changes | $7.89 Million | +41.51% |
| Total Change | $- | -27.27% |
Book Value vs Market Value Analysis
This analysis compares PDS Biotechnology Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-4.48 | $0.63 | x |
| 2013-12-31 | $-20.32 | $0.63 | x |
| 2014-12-31 | $-36.85 | $0.63 | x |
| 2015-12-31 | $87.33 | $0.63 | x |
| 2016-12-31 | $61.87 | $0.63 | x |
| 2017-12-31 | $41.04 | $0.63 | x |
| 2018-12-31 | $7.49 | $0.63 | x |
| 2019-12-31 | $2.40 | $0.63 | x |
| 2020-12-31 | $1.62 | $0.63 | x |
| 2021-12-31 | $2.47 | $0.63 | x |
| 2022-12-31 | $1.54 | $0.63 | x |
| 2023-12-31 | $0.84 | $0.63 | x |
| 2024-12-31 | $0.52 | $0.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PDS Biotechnology Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -197.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.39x
- Recent ROE (-197.90%) is below the historical average (-67.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.36 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.35 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.42 Million |
| 2015 | -22.93% | 0.00% | 0.00x | 1.09x | $-40.33 Million |
| 2016 | -43.48% | 0.00% | 0.00x | 1.24x | $-47.75 Million |
| 2017 | -81.54% | 0.00% | 0.00x | 1.48x | $-57.10 Million |
| 2018 | -136.96% | 0.00% | 0.00x | 1.21x | $-43.85 Million |
| 2019 | -59.83% | 0.00% | 0.00x | 1.24x | $-8.17 Million |
| 2020 | -54.73% | 0.00% | 0.00x | 1.14x | $-17.56 Million |
| 2021 | -26.77% | 0.00% | 0.00x | 1.06x | $-23.24 Million |
| 2022 | -92.85% | 0.00% | 0.00x | 1.75x | $-45.26 Million |
| 2023 | -164.33% | 0.00% | 0.00x | 2.27x | $-45.56 Million |
| 2024 | -197.90% | 0.00% | 0.00x | 2.39x | $-39.51 Million |
Industry Comparison
This section compares PDS Biotechnology Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | $9.45 Million | 0.00% | 2.67x | $30.19 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |